ETERNITY BIOSCIENCE, INC
  • Home
  • About
  • Pipeline
  • News
    • Press
    • Meetings & Publications
  • Careers
    • Meet Our Scientists
    • Openings
  • Contact
  • Home
  • About
  • Pipeline
  • News
    • Press
    • Meetings & Publications
  • Careers
    • Meet Our Scientists
    • Openings
  • Contact

PIPELINE 

 - Since 2009, EBI team has discovered novel inhibitors against ALK, BRAF, MEK, EZH2, and BTK.

- Two BTK inhibitors have been licensed to TG Therapeutics for a total value of $347 million.
​
- EZH2 and BTK inhibitors are currently under clinical development in multiple countries.
Picture
Proudly powered by Weebly